AstraZeneca’s asthma drug shows promising results

The company’s new asthma drug candidate benralizumab has shown positive results in a phase IIb trial


The study showed that benralizumab reduced asthma exacerbations by 40-70 percent

AstraZeneca's (AZ) benralizumab, a novel investigational monoclonal antibody for treatment in patients with severe, uncontrolled asthma and elevated levels of eosinophil has shown a positive result in mid-stage, phase IIb clinical study.

The trial met its primary endpoint, with patients on benralizumab experiencing a statistically significant reduction in their asthma exacerbation rate versus placebo over a year.

The study showed that the drug reduced asthma exacerbations by approximately 40-70 percent, depending on the dose received and baseline blood eosinophil level.

Mr Bing Yao, head of respiratory, inflammation and autoimmunity operations at AZ's MedImmune unit said, "Asthma is a highly heterogeneous disease and this data advances our understanding of patient subtypes, potential biomarkers, and targeted therapies."



Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email